Abcellera Biologics - Common Shares (ABCL) closed at $11.95 on November 11, 2026, down 4.1% from the previous close, on volume of 2,613,053 shares (30-day average 3,984,353).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 19, 2026 | Call Spread | 15-Jan-2710 : 15 C | 2,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
AbCL635 Drives AbCellera’s Positive Earnings Call Outlook
TipRanks (Tue, 10-Nov 7:13 PM ET)
AbCellera: Encouraging ABCL635 Data Supports Buy Rating; $25 Price Target Unchanged
TipRanks (Tue, 10-Nov 6:25 PM ET)
TipRanks (Tue, 10-Nov 8:10 AM ET)
Cantor Fitzgerald Sticks to Their Buy Rating for AbCellera Biologics (ABCL)
TipRanks (Tue, 10-Nov 7:56 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Tue, 10-Nov 7:50 AM ET)
AbCellera Biologics GAAP EPS of -$0.13 beats by $0.05, revenue of $10.6M beats by $4.35M
Seeking Alpha News (Mon, 9-Nov 4:19 PM ET)
AbCellera Reports Q3 2026 Business Results
Business Wire (Mon, 9-Nov 4:05 PM ET)
Here are the major earnings after the close Monday
Seeking Alpha News (Mon, 9-Nov 10:00 AM ET)
AbCellera Biologics Q3 2026 Earnings Preview
Seeking Alpha News (Sun, 8-Nov 5:35 PM ET)
Seeking Alpha News (Sun, 8-Nov 10:00 AM ET)
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Abcellera Biologics - Common Shares trades on the NASDAQ stock market under the symbol ABCL.
As of November 11, 2026, ABCL stock price declined to $11.95 with 2,613,053 million shares trading.
ABCL has a beta of 2.49, meaning it tends to be more sensitive to market movements. ABCL has a correlation of 0.09 to the broad based SPY ETF.
ABCL has a market cap of $3.90 billion. This is considered a Mid Cap stock.
Last quarter Abcellera Biologics - Common Shares reported $11 million in Revenue and -$.13 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.05.
In the last 3 years, ABCL traded as high as $15.02 and as low as $1.89.
The top ETF exchange traded funds that ABCL belongs to (by Net Assets): IBB, IDNA, SPDW, FDT, ONEQ.
ABCL has outperformed the market in the last year with a return of +196.5%, while the SPY ETF gained +12.6%. In the last 3 month period, ABCL beat the market returning +27.9%, while SPY returned -1.5%. However, in the most recent 2 weeks ABCL has underperformed the stock market by returning -6.9%, while SPY returned -1.3%.
ABCL support price is $11.77 and resistance is $13.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABCL shares will trade within this expected range on the day.
